Compare BioNTech SE - ADR (BNTX) vs Dover Corp (DOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Dover Corp — how do they compare? BioNTech SE - ADR trades at $93.1 (market cap $23.31B), while Dover Corp trades at $207.87 (market cap $28.07B). The key difference: Dover Corp is the larger of the two by market cap, and Dover Corp pays a 1.01% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | DOV | |
|---|---|---|
Market Cap | $23.31B | $28.07B |
Sector | Health | Industrials |
52-Week High | $119.34 | $233.31 |
52-Week Low | $83.89 | $161.16 |
Enterprise Value | $6.60B | $29.58B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Dover Corporation (DOV) trades at $210.1, down 0.49% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported strong Q2 2026 results with EPS of $2.74, exceeding expectations, and raised full-year guidance. Recent dividend increases and strategic acquisitions, such as Cloeren, highlight management's confidence in growth. Valuation ratios like P/E of 25.21 and ROE of 14.98% reflect solid profitability, though the stock faces resistance near $212.
The outlook for DOV is positive, driven by robust fundamentals and analyst consensus favoring a buy rating with a $232.33 price target. Risks include market volatility and execution challenges from acquisitions, but diversified end-market exposure and margin expansion support upside potential for investors seeking steady income and growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
